PDF herunterladen
Semin Thromb Hemost 2019; 45(04): 342-347
DOI: 10.1055/s-0039-1687890
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Disseminated Intravascular Coagulation in Cancer: An Update

Marcel Levi
1   Department of Medicine, University College London Hospitals, London, United Kingdom
2   Biomedical Research Centre, University College London Hospitals, London, United Kingdom
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. April 2019 (online)

    Lizenzen und Reprints

Abstract

Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation proteins and thrombocytes (which may cause bleeding complications). The clinical course of DIC in patients with malignancies is typically less intense compared with DIC complicating alternative clinical settings, including systemic inflammatory responses following infection or traumatic injury. A more slowly proceeding, less fulminant, and widespread hemostatic derangement can remain asymptomatic. Eventually, the ongoing consumption may result in low levels of platelets and coagulation factors, and bleeding complications (frequently localized at the site of the tumor or distant metastases) may be the first clinical manifestation of DIC. An alternative clinical scenario is dominated by thrombotic complications, ranging from clinically manifest vascular thrombosis to microvascular platelet plugs. The main principle of DIC management is adequate treatment of the precipitating disorder; however, there are clinical presentations that may require additional supportive strategies specifically aimed at the amelioration of the coagulopathy.

Keywords

disseminated intravascular coagulation - hemorrhage - thrombosis - thrombotic microangiopathy - cancer - coagulation - fibrinolysis
 

  • References

  • 1 Levi M. Cancer-related coagulopathies. Thromb Res 2014; 133 (Suppl. 02) S70-S75
    PubMedGoogle Scholar
  • 2 Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 2009; 22 (01) 129-136
    CrossrefPubMedGoogle Scholar
  • 3 Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102 (06) V187-V194
    CrossrefPubMedGoogle Scholar
  • 4 Levi M. Cancer and thrombosis. Clin Adv Hematol Oncol 2003; 1 (11) 668-671
    PubMedGoogle Scholar
  • 5 Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86 (03) 828-833
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001; 27 (06) 593-604
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Sarris AH, Kempin S, Berman E. , et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79 (05) 1305-1310
    CrossrefPubMedGoogle Scholar
  • 8 Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MG, Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70 (01) 43-48
    CrossrefPubMedGoogle Scholar
  • 9 Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28 (Suppl. 03) 50-60
    PubMedGoogle Scholar
  • 10 Libourel EJ, Klerk CPW, van Norden Y. , et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood 2016; 128 (14) 1854-1861
    PubMedGoogle Scholar
  • 11 Feinstein DI. Disseminated intravascular coagulation in patients with solid tumors. Oncology (Williston Park) 2015; 29 (02) 96-102
    PubMedGoogle Scholar
  • 12 Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001; 106 (1-2): 52-56
    CrossrefPubMedGoogle Scholar
  • 13 Levi M. Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. Thromb Res 2018; 164 (Suppl. 01) S77-S81
    CrossrefPubMedGoogle Scholar
  • 14 Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74 (01) 278-281
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease [see comments]. Nat Med 1996; 2 (02) 209-215
    CrossrefPubMedGoogle Scholar
  • 16 Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost 2008; 34 (02) 143-145
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92 (18) 8205-8209
    CrossrefPubMedGoogle Scholar
  • 18 Zhang Y, Deng Y, Luther T. , et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94 (03) 1320-1327
    CrossrefPubMedGoogle Scholar
  • 19 Nadir Y, Vlodavsky I, Brenner B. Heparanase, tissue factor, and cancer. Semin Thromb Hemost 2008; 34 (02) 187-194
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 20 Milsom C, Yu J, May L, Magnus N, Rak J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. Semin Thromb Hemost 2008; 34 (02) 170-181
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 21 Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology 2011; 81 (02) 119-125
    CrossrefPubMedGoogle Scholar
  • 22 Kwaan HC, McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat Res 2009; 148: 43-66
    PubMedGoogle Scholar
  • 23 Tallman MS. The thrombophilic state in acute promyelocytic leukemia. Semin Thromb Hemost 1999; 25 (02) 209-215
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 1994; 8 (Suppl. 02) S20-S26
    PubMedGoogle Scholar
  • 25 Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22 (01) 153-163
    CrossrefPubMedGoogle Scholar
  • 26 Mitrovic M, Suvajdzic N, Elezovic I. , et al. Thrombotic events in acute promyelocytic leukemia. Thromb Res 2015; 135 (04) 588-593
    CrossrefPubMedGoogle Scholar
  • 27 Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66 (05) 857-868
    CrossrefPubMedGoogle Scholar
  • 28 Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19 (05) 580-596
    PubMedGoogle Scholar
  • 29 Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14 (04) 495-504
    PubMedGoogle Scholar
  • 30 Snyder Jr HW, Mittelman A, Oral A. , et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 1993; 71 (05) 1882-1892
    CrossrefPubMedGoogle Scholar
  • 31 Guinan EC, Tarbell NJ, Niemeyer CM, Sallan SE, Weinstein HJ. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72 (02) 451-455
    CrossrefPubMedGoogle Scholar
  • 32 Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35 (06) 1336-1344
    CrossrefPubMedGoogle Scholar
  • 33 Rabinowe SN, Soiffer RJ, Tarbell NJ. , et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991; 77 (08) 1837-1844
    CrossrefPubMedGoogle Scholar
  • 34 Levi M, Scully M, Singer M. The role of ADAMTS-13 in the coagulopathy of sepsis. J Thromb Haemost 2018; 16 (04) 646-651
    CrossrefPubMedGoogle Scholar
  • 35 Jackson AM, Rose BD, Graff LG. , et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101 (01) 41-44
    PubMedGoogle Scholar
  • 36 Garcia G, Atallah JP. Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract 2017; 23 (02) 135-142
    CrossrefPubMedGoogle Scholar
  • 37 Chappell ME, Keeling DM, Prentice HG, Sweny P. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?. Bone Marrow Transplant 1988; 3 (04) 339-347
    PubMedGoogle Scholar
  • 38 Holler E, Kolb HJ, Hiller E. , et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73 (07) 2018-2024
    CrossrefPubMedGoogle Scholar
  • 39 Collins PW, Gutteridge CN, O'Driscoll A. , et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant 1992; 10 (06) 499-506
    PubMedGoogle Scholar
  • 40 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007; 33 (08) 787-797
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 41 Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990; 8 (06) 511-518
    CrossrefPubMedGoogle Scholar
  • 42 Conway EM, Van de Wouwer M, Pollefeyt S. , et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196 (05) 565-577
    CrossrefPubMedGoogle Scholar
  • 43 Levi M, ten Cate JW, Dooijewaard G, Sturk A, Brommer EJ, Agnelli G. DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Haemost 1989; 62 (02) 686-689
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 44 Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43 (02) 77-89
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 45 Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27 (01) 3-9
    PubMedGoogle Scholar
  • 46 Wada H, Kaneko T, Ohiwa M. , et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44 (02) 101-105
    CrossrefPubMedGoogle Scholar
  • 47 Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30 (5, Suppl): S220-S224
    CrossrefPubMedGoogle Scholar
  • 48 Straub PW. Diffuse intravascular coagulation in liver disease?. Semin Thromb Hemost 1977; 4 (01) 29-39
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 49 Levi M. Disseminated intravascular coagulation: a disease-specific approach. Semin Thromb Hemost 2010; 36 (04) 363-365
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 50 Seligsohn U. Disseminated intravascular coagulation. In: Handin RI, Lux SE, Stossel TP. , eds. Blood: Principles and Practice of Hematology. Philadelphia, PA: J.B. Lippincott; 2000
    Google Scholar
  • 51 Sack Jr GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56 (01) 1-37
    PubMedGoogle Scholar
  • 52 Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a review. Am Heart J 1987; 113 (03) 773-784
    CrossrefPubMedGoogle Scholar
  • 53 Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood 2018; 131 (08) 845-854
    CrossrefPubMedGoogle Scholar
  • 54 Wada H, Thachil J, Di Nisio M. , et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 (e-pub ahead of print). doi:10.1111/jth.12155
    PubMedGoogle Scholar
  • 55 Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M. ; Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13 (04) 671-675
    CrossrefPubMedGoogle Scholar
  • 56 Levi M. Management of cancer-associated disseminated intravascular coagulation. Thromb Res 2016; 140 (Suppl. 01) S66-S70
    CrossrefPubMedGoogle Scholar
  • 57 Martí-Carvajal AJ, Anand V, Solà I. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev 2015; (06) CD008562
    PubMedGoogle Scholar
  • 58 Thachil J, Falanga A, Levi M, Liebman H, Di NM. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. Reply J Thromb Haemost 2015; 13 (04) 671-675
    PubMedGoogle Scholar
  • 59 Kakkar AK, Kadziola Z, Williamson RC. Low molecular weight heparin therapy and survival in advanced cancer. Blood 2002; 100: 148a
    CrossrefPubMedGoogle Scholar
  • 60 Schünemann HJ, Ventresca M, Crowther M. , et al; IPDMA heparin use in cancer patients research group. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open 2016; 6 (04) e010569
    CrossrefPubMedGoogle Scholar
  • 61 Di Minno MND, Ageno W, Lupoli R. , et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J 2017; 50 (03) 1701097
    CrossrefPubMedGoogle Scholar
  • 62 Cook DJ, Crowther MA, Meade MO, Douketis J. ; VTE in the ICU Workshop Participants. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20 (04) 309-313
    CrossrefPubMedGoogle Scholar
  • 63 Patel R, Cook DJ, Meade MO. , et al; Burden of Illness in venous ThromboEmbolism in Critical care (BITEC) Study Investigators; Canadian Critical Care Trials Group. Burden of illness in venous thromboembolism in critical care: a multicenter observational study. J Crit Care 2005; 20 (04) 341-347
    CrossrefPubMedGoogle Scholar
  • 64 Niers TM, Klerk CP, DiNisio M. , et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61 (03) 195-207
    CrossrefPubMedGoogle Scholar
  • 65 Corrigan Jr JJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. N Engl J Med 1970; 283 (15) 778-782
    CrossrefPubMedGoogle Scholar
  • 66 Audibert G, Lambert H, Toulemonde F. , et al. Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy [in French]. J Mal Vasc 1987; 12 (Suppl B): 147-151
    PubMedGoogle Scholar
  • 67 Feinstein DI. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988; 14 (04) 351-362
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 68 Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10 (04) 222
    CrossrefPubMedGoogle Scholar
  • 69 Saito H, Maruyama I, Shimazaki S. , et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 70 Matsushita T, Watanabe J, Honda G. , et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res 2014; 133 (05) 772-781
    CrossrefPubMedGoogle Scholar
  • 71 Yokoyama H, Takahashi N, Katsuoka Y. , et al; Tohoku Hematology Forum. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol 2017; 105 (05) 606-613
    CrossrefPubMedGoogle Scholar
  • 72 Asakura H, Takahashi H, Tsuji H. , et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res 2014; 133 (03) 364-370
    CrossrefPubMedGoogle Scholar
  • 73 Tamura K, Saito H, Asakura H. , et al. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial. Int J Clin Oncol 2015; 20 (04) 821-828
    CrossrefPubMedGoogle Scholar
  • 74 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
    CrossrefPubMedGoogle Scholar
  • 75 Wheater MJ, Mead GM, Bhandari S, Fennell J. Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma. J Clin Oncol 2008; 26 (06) 1008-1010
    CrossrefPubMedGoogle Scholar
  • 76 Shenoy A, Savani BN, Barrett AJ. Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13 (05) 622-623
    CrossrefPubMedGoogle Scholar
  • 77 Erikci AA, Ozturk A, Sayan O. Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia. Blood Coagul Fibrinolysis 2006; 17 (04) 323-324
    CrossrefPubMedGoogle Scholar